OpenAI updates GPT‑Rosalind for enterprise life sciences and debuts LifeSciBench
OpenAI announced a research preview update to GPT‑Rosalind that combines GPT‑5.5 agentic coding and tool‑use with stronger intelligence for drug‑discovery domains such as medicinal chemistry and genomics. The company also introduced LifeSciBench, an externally expert‑judged benchmark designed to measure end‑to‑end performance across core life sciences workflows.